Navigation Links
OREXIGEN(R) Therapeutics Receives Notice of Allowance for U.S. Patent Covering the Composition of Matter in OREX-003
Date:7/29/2008

e weight gain associated with atypical antipsychotics may impact compliance with treatment and, in turn, place patients at an increased risk of relapse. In contrast, staying on treatment and gaining significant body weight may place them at risk for a number of obesity-related metabolic disorders. We believe that OREX-003 has the potential to eliminate this conundrum."

Despite the commercial success of Zyprexa(R), IMS data shows that new prescriptions have declined by approximately 50% from 2003 to 2007, likely as a result of side effects, particularly excessive weight gain. According to the package insert for Zyprexa(R), 56% of patients gained 7% or more of baseline body weight in long-term clinical trials.

If issued, this patent will also cover zonisamide in combination with other atypical antipsychotics, including clozapine, risperidone, quetiapine, aripiprazole and ziprasidone. Zonisamide is also a component of the Company's obesity treatment candidate Empatic(TM), which is in the later stages of Phase II clinical development.

About Orexigen Therapeutics

Orexigen(R) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave(R), which is in Phase III clinical trials, and Empatic(TM), which is in the later stages of Phase II clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Beyond obesity, Orexigen is developing drug combinations for use in schizophrenia and obsessive-compulsive disorder. Further information about the company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you t
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
2. Cara Therapeutics Secures $12.3 Million in Series C Extension Financing
3. United Therapeutics to Announce Second Quarter 2008 Financial Results Before Market Open on Thursday, July 31, 2008
4. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
5. Duska Therapeutics Submits Phase 3 ATPace(TM) Protocol to FDA for Comment
6. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
7. CV Therapeutics to Announce 2008 Second Quarter Financial Results on Thursday, July 31, 2008
8. Lorus Therapeutics Reports Fourth Quarter Results for Fiscal Year 2008
9. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
10. Northwest Biotherapeutics to Present at Next Generation Vaccine Conference
11. Organizational Changes at Silence Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... difficult to manufacture proteins including biosimilar therapeutics, today ... for the second quarter ended June 30, 2014. ... initial public offering, we have the capital to ... from our proprietary protein expression platform," stated Bertrand ...
(Date:8/29/2014)... electrons, but one of the most promising technologies for ... on light (photons) instead of electrons. First, it is ... single photons and control their direction. Researchers around the ... this control, but now scientists at the Niels Bohr ... photons emitted one at a time and in a ...
(Date:8/29/2014)... The global companion diagnostics market ... It is expected to grow at a CAGR ... valued at $1.8 billion in 2013, according to ... , For more information regarding analysis details and ... research report, titled “Companion Diagnostics Market (Breast Cancer, ...
(Date:8/29/2014)... According to a new market report published ... market was valued at USD 3,754.6 million in 2012 and ... 2019at a CAGR of 5.9% from 2013 to 2019. , ... is afflicted by bone and joint disorders, and this number ... has and will continue to increase the demand for orthobiologics. ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... chief becomes marketer Rockwell reports dividend ... patent-strategy conference RoleFlow Software Targets Human Resources Efficiency ... ,The Wisconsin Alumni Association has created a Web site to ... . The site uses MonsterTrak , a service of ...
... What does it mean to the biotech community to have ... be thoroughly addressed at the Wisconsin Life Sciences and ... Spawns Novel Therapies. The conference will be held November 16 ... showcase about 20 companies, 11 from Wisconsin, will strut ...
... to those risk-addicted Californians: Saddled with a debt running into ... their credit cards and pinch pennies. They borrow even more ... happened last week when California voters overwhelmingly approved Proposition 71, ... in bonds to pay for human embryonic stem cell research. ...
Cached Biology Technology:Tech Digest: whats moving in the Midwest (11/3/04) 2Life-sciences conference to feature novel research with clinical potential 2California stem cell initiative should wake up Washington and Madison 2California stem cell initiative should wake up Washington and Madison 3
(Date:8/28/2014)... of bacterial culprits that may drive inflammatory bowel diseases ... patients, own intestinal immune responses as a guide. , ... Cell . , Trillions of bacteria exist within ... in the development and progression of IBD. Yet it,s ... affect a person,s susceptibility to IBD and its potential ...
(Date:8/28/2014)... Minn. A Mayo Clinic researcher and his collaborators ... up and enhance the process of re-engineering cells for ... uses network biology methods to aid stem cell engineering. ... engineering are described in two back-to-back papers in the ... a broad range of uses for all types of ...
(Date:8/28/2014)... -- Privacy Advocate and Senior Staff Attorney at the Electronic ... lineup of biometric and mobile commerce experts set to ... in Tampa, Florida on September ... Steven Rahman, Director, Technology and Strategy at Samsung, and Philippe ... of this year,s event is Mobility at the Crossroads ...
Breaking Biology News(10 mins):Yale study identifies possible bacterial drivers of IBD 2New tool aids stem cell engineering for medical research 2Biometrics UnPlugged Welcomes the Electronic Frontier Foundation's Jennifer Lynch to the Mobility at the Crossroads of Commerce and Privacy Summit 2
... X syndrome (FXS) is the most common hereditary form ... from attention deficit and/or hyperactivity disorder (ADHD), which complicates ... medication such as Ritalin is often successfully used to ... it is effective in children with mental retardation, it ...
... choose the nesting location of their first breeding season has ... a new University of Maryland/National Zoo study of the ... in their first year may help determine where they breed ... significantly affect the population as climate change makes their winter ...
... January 2001, the world held its breath when the tanker ... and began breaking up in the heart of one of ... the Galapagos Islands. At risk were vast numbers of ... Charles Darwin that contributed to his landmark theory of evolution ...
Cached Biology News:Effective ADHD treatment found for children with fragile X syndrome 2Early environment may be key to determining bird migration location 2Early environment may be key to determining bird migration location 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 2First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 3First wind turbines on Galapagos Islands will halve diesel imports, reduce risk of future oil spills 4
Kinase Buffer can be used to assay protein kinase activity...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
Anti-Kusabira Orange Monoclonal Antibody Description: 100 g Research Focus: tag Storage: -20C Shipping Temperature: 4C...
...
Biology Products: